Comparative Pharmacology
Head-to-head clinical analysis: RAMIPRIL versus VASERETIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RAMIPRIL versus VASERETIC.
RAMIPRIL vs VASERETIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ramipril is a prodrug that is hydrolyzed in the liver to its active metabolite ramiprilat, which inhibits angiotensin-converting enzyme (ACE), thereby decreasing angiotensin II production, reducing vasoconstriction, aldosterone secretion, and sodium retention.
Vaseretic is a combination of enalapril maleate (an angiotensin-converting enzyme inhibitor) and hydrochlorothiazide (a thiazide diuretic). Enalapril inhibits ACE, reducing angiotensin II formation, decreasing aldosterone secretion, and lowering blood pressure. Hydrochlorothiazide increases sodium and chloride excretion by inhibiting the Na+-Cl- symporter in the distal convoluted tubule, leading to diuresis and vasodilation.
Initial: 2.5 mg orally once daily; Maintenance: 2.5-20 mg/day in 1-2 divided doses; Maximum: 20 mg/day.
One tablet (10 mg enalapril maleate/25 mg hydrochlorothiazide) orally once daily; may increase to 2 tablets daily if needed.
None Documented
None Documented
Clinical Note
moderateRamipril + Torasemide
"The risk or severity of adverse effects can be increased when Ramipril is combined with Torasemide."
Clinical Note
moderateRamipril + Etacrynic acid
"The risk or severity of adverse effects can be increased when Ramipril is combined with Etacrynic acid."
Clinical Note
moderateRamipril + Furosemide
"The risk or severity of adverse effects can be increased when Ramipril is combined with Furosemide."
Clinical Note
moderateRamipril + Bumetanide
Terminal half-life of ramiprilat is 13–17 hours (prolonged to 50 hours in renal impairment). Accumulation half-life is 110 hours after multiple doses.
Enalaprilat: 35–38 hours (terminal). Clinically, effective half-life ~11 hours. Prolonged in renal impairment (CrCl <30 mL/min: up to 60 hours).
Primarily renal (60% as unchanged drug and metabolites) and fecal (40% via biliary elimination).
Renal: 60% (enalaprilat); biliary/fecal: 33% (enalaprilat). Unchanged enalapril: <5% in urine.
Category D/X
Category C
ACE Inhibitor
ACE Inhibitor/Diuretic Combination
"The risk or severity of adverse effects can be increased when Ramipril is combined with Bumetanide."